- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Syngene International names Peter Bains as MD, CEO

Bengaluru: Syngene International, a listed subsidiary of Biocon Limited, has announced the appointment of Peter Bains as an Additional Director, designated him as Managing Director & Chief Executive Officer (a Key Managerial Personnel) of the Company effective April 1, 2025.
In a BSE filing, Syngene stated, "We wish to inform you that the Board of Directors, pursuant to the recommendation of the Nomination and Remuneration Committee (‘NRC’), approved the appointment of Mr. Peter Bains as an Additional Director, designated as Managing Director & Chief Executive Officer (a Key Managerial Personnel) of the Company effective April 1, 2025 subject to the approval of the shareholders of the Company,"
Peter Bains, 67 years, holds a bachelor’s degree in Science (Combined honours in Zoology and Physiology) from University of Sheffield, United Kingdom. He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels with an extensive track record of leadership and success in building companies, businesses, teams and brands for over 30 years. Bains brings in differentiating characteristics with extensive experience in Biopharmaceuticals across business and technology segmentation (Biotech, Vaccines, Branded Generics, Life Sciences, CRO) and geography encompassing both developed and emerging markets.
Bains had served as the Chief Executive Officer (CEO) and Member of the Board of Syngene International Limited for nearly six years, starting in 2010. During his tenure, he successfully led the company to its public listing in 2015.
He joined back the Biocon Group as an Independent Director in Biocon Limited in December 2022 and later was appointed as the Group CEO in September 2023. He also held the position of CEO at Sosei Group, a publicly traded biopharmaceutical company in Japan.
Prior to these roles, Bains had a distinguished 23-year career at GlaxoSmithKline (GSK), where he held several senior positions, including Head of Global Marketing and Senior Vice President of Commercial Development for GSK’s International region.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751